BIS-001ER
Phase 1/2Active 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focal Impaired Awareness Seizures
Conditions
Focal Impaired Awareness Seizures
Trial Timeline
Apr 10, 2018 → Dec 30, 2026
NCT ID
NCT03474770About BIS-001ER
BIS-001ER is a phase 1/2 stage product being developed by Supernus Pharmaceuticals for Focal Impaired Awareness Seizures. The current trial status is active. This product is registered under clinical trial identifier NCT03474770. Target conditions include Focal Impaired Awareness Seizures.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03474770 | Phase 1/2 | Active |
Competing Products
20 competing products in Focal Impaired Awareness Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 85 |
| Dapagliflozin | AstraZeneca | Approved | 85 |
| Enfuvirtide + Tenofovir-Emtricitabine | Roche | Phase 2 | 52 |
| CCX140-B | Amgen | Phase 2 | 51 |
| PF-06730512 | Pfizer | Phase 2 | 51 |
| Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Pfizer | Approved | 84 |
| VX-147 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-147 | Vertex Pharmaceuticals | Phase 1 | 32 |
| IXP | Vertex Pharmaceuticals | Phase 1 | 32 |
| fresolimumab + fresolimumab + Placebo | Sanofi | Phase 2 | 51 |
| GC1008 + GC1008 + GC1008 + GC1008 | Sanofi | Phase 1 | 32 |
| frexalimab + brivekimig + rilzabrutinib + placebo | Sanofi | Phase 2 | 51 |
| Vivaglobin | CSL | Phase 2 | 51 |
| UCB0942 | UCB | Phase 2 | 49 |
| Levetiracetam + Carbamazepine + Lamotrigine | UCB | Approved | 82 |
| Brivaracetam + Brivaracetam | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Lacosamide | UCB | Pre-clinical | 20 |
| ARGX-117 | Argenx | Phase 2 | 49 |